CalciMedica
Clinical Trials
9
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- CalciMedica, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06374797
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Chandler Regional Hospital, Chandler, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- CalciMedica, Inc.
- Registration Number
- NCT05171920
- Locations
- 🇺🇸
Regions Hospital, Saint Paul, Minnesota, United States
🇺🇸Methodist Hospital, Saint Paul, Minnesota, United States
🇺🇸JPS Health, Fort Worth, Texas, United States
A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS
- Conditions
- Systemic Inflammatory Response SyndromeAcute Pancreatitis
- Interventions
- Drug: CM-4620 Injectable Emulsion or CM-4620-IEOther: Placebo
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- CalciMedica, Inc.
- Target Recruit Count
- 216
- Registration Number
- NCT04681066
- Locations
- 🇺🇸
Long Beach Medical Center, Long Beach, California, United States
🇺🇸LA County Hospital - USC, Los Angeles, California, United States
🇺🇸Cedars Sinai, Los Angeles, California, United States
A Study of Auxora in Patients With Critical COVID-19 Pneumonia
- Conditions
- Pneumonia
- Interventions
- Drug: CM4620-IE (Injectable Emulsion)Drug: Placebo
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- CalciMedica, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04661540
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
A Study of Auxora in Patients With Severe COVID-19 Pneumonia
- Conditions
- Pneumonia
- Interventions
- Drug: Auxora (Part 1)Drug: Standard of Care (Part 1)Drug: Auxora (Part 2)Drug: Placebo (Part 2)
- First Posted Date
- 2020-04-14
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- CalciMedica, Inc.
- Target Recruit Count
- 314
- Registration Number
- NCT04345614
- Locations
- 🇺🇸
Long Beach Memorial, Long Beach, California, United States
🇺🇸University of Southern California / LA County, Los Angeles, California, United States
🇺🇸Sharp Memorial San Diego, San Diego, California, United States
- Prev
- 1
- 2
- Next
News
CalciMedica Secures $32.5M Credit Facility to Advance CRAC Channel Inhibitor Development
CalciMedica has secured a $32.5M credit facility from Avenue Venture Opportunities Fund, with an initial $10M tranche extending cash runway into mid-2026.
Auxora Shows 63% Mortality Reduction in COVID-19 Patients with Acute Kidney Injury
Post-hoc analysis of CARDEA Phase 2 trial reveals Auxora reduced mortality by 62.7% in COVID-19 patients with acute kidney injury compared to placebo, with benefits persisting through 60 days.
Zegocractin Shows Promise in Reducing Acute Pancreatitis Symptoms in Phase 2 Trial
Zegocractin, a CRAC channel inhibitor, significantly reduced the time to solid food tolerance in acute pancreatitis patients with systemic inflammatory response syndrome (SIRS).